Bank of Montreal Can Purchases New Position in 908 Devices Inc. (NASDAQ:MASS)

Bank of Montreal Can purchased a new position in shares of 908 Devices Inc. (NASDAQ:MASS - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 56,310 shares of the company's stock, valued at approximately $124,000. Bank of Montreal Can owned 0.16% of 908 Devices at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in MASS. State Street Corp boosted its holdings in shares of 908 Devices by 1.2% in the third quarter. State Street Corp now owns 479,044 shares of the company's stock valued at $1,662,000 after acquiring an additional 5,704 shares in the last quarter. Geode Capital Management LLC increased its stake in 908 Devices by 1.2% in the third quarter. Geode Capital Management LLC now owns 567,788 shares of the company's stock valued at $1,970,000 after purchasing an additional 6,634 shares during the last quarter. LPL Financial LLC grew its position in 908 Devices by 13.0% during the fourth quarter. LPL Financial LLC now owns 63,287 shares of the company's stock valued at $139,000 after acquiring an additional 7,295 shares during the period. B. Riley Wealth Advisors Inc. purchased a new stake in 908 Devices during the third quarter worth approximately $45,000. Finally, Prudential Financial Inc. purchased a new stake in shares of 908 Devices during the fourth quarter worth about $34,000. 88.06% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on the company. Stephens reiterated an "overweight" rating and issued a $6.00 price target on shares of 908 Devices in a research note on Wednesday, January 15th. Weiss Ratings reissued a "sell (d-)" rating on shares of 908 Devices in a research note on Thursday, April 24th. Two research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat, 908 Devices has a consensus rating of "Moderate Buy" and an average price target of $5.33.

908 Devices Stock Performance

Shares of NASDAQ:MASS traded down $0.02 on Thursday, hitting $5.42. The stock had a trading volume of 51,214 shares, compared to its average volume of 980,630. The company has a market capitalization of $191.31 million, a price-to-earnings ratio of -3.06 and a beta of 0.30. The firm's 50 day moving average price is $4.02 and its 200-day moving average price is $3.12. 908 Devices Inc. has a twelve month low of $1.81 and a twelve month high of $7.48.

908 Devices Company Profile

908 Devices Inc, a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, pharma/biopharma, forensics, and adjacent markets. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and Maverick, an optical in-line analyzer that offers real-time monitoring and control of multiple bioprocess parameters, including glucose, lactate, and total biomass in mammalian cell cultures, as well as provides process fingerprint data to support large-scale efforts in predictive bioprocess modeling.